FDA review milestones are progressing: the AdvSM New Drug Application was submitted on June 30, with a potential PDUFA date of November 30 for GIST patients and December 30 for NonAdvSM patients. This sets a clear path toward regulatory decision later this year. Overall, the news is supportive but contingent on FDA approval.
FDA review milestones are progressing: the AdvSM New Drug Application was submitted on June 30, with a potential PDUFA date of November 30 for GIST patients and December 30 for NonAdvSM patients. This sets a clear path toward regulatory decision later this year. Overall, the news is supportive but contingent on FDA approval.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
